Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

propriate therapies for their patients. This leads us to two significant market opportunities."

The first market opportunity is represented by breast cancer patients being treated in the adjuvant setting. These patients are generally newly diagnosed with breast cancer, have had surgery and are now embarked on a first course of treatment to supplement the surgical procedure. There are approximately 200,000 new cases of breast cancer each year. Nearly all of these patients are candidates for adjuvant treatment and will therefore be candidates for our planned HERmark adjuvant breast cancer assay. The second market opportunity is represented by patients with metastatic breast cancer. These are patients for whom the cancer has spread beyond the breast, and in many cases multiple treatments may have already been provided. There are an additional 60,000 women annually who are newly diagnosed with Stage IV breast cancer or who have progressed from earlier stages of disease. "We are proceeding on parallel paths to generate clinical data to validate the ability of HERmark to predict patient response in each of these clinical settings," continued Young.

"We have recently begun our work in the adjuvant use of Herceptin with the initiation of a pivotal study in up to 1,600 patient samples from a well controlled and highly credible clinical study," said Young. "This study is designed to evaluate HERmark as a tool for predicting response to Herceptin in the adjuvant setting and is a very important platform for validating the VeraTag technology and the first HERmark products. We have already received and processed the first samples and expect to receive the remaining samples for processing over the next several months."

Monogram is continuing its evaluation of HERmark in metastatic breast cancer patients, where in three separate cohorts of patients involving a total of approximately 250 patients, consistent relationships have been identified between assay measurem
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... JOLIET, Ill. , Jan. 15, 2014  Bill Jacobs Automotive, ... , is teaming up with the Heartland Blood Center ... annual blood drive. The drive takes place Saturday, Jan. 18 ... a.m. - 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... ... of Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) October 2, 2009 ... (SLV) series specifically for biotech and specialty pharma companies. The new series includes Situational ...
... ... Orange County Emerging Growth Awards, recognizing companies headquartered in Orange County that have reached ... 12 months and that have made a positive impact on the local economy. ... Orange County, CA ...
... a plane the consequences can be fatal, not only for ... the aircraft fuselage, causing stresses in the material which can ... skin will detect such damage at an early stage and ... they don,t need any cables or batteries. They draw their ...
Cached Biology Technology:Perceptum Group Announces New Situational Leadership V Series 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 3Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 4Energy-autonomous sensors for aircraft 2
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may be ... be more careful. In the wild, a plant whose seeds ... risk disaster. More than just an insurance policy against late ... dormancy has long-term advantages too: Plants whose seeds put ... more species, finds in a team of researchers working at ...
(Date:4/17/2014)... Ill. A drug under clinical trials to treat ... broad-spectrum drugs that act against various bacteria, fungal infections ... by University of Illinois chemists and collaborators. , Led ... team determined the different ways the drug SQ109 attacks ... to target other pathogens from yeast to malaria ...
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... CABI both bring a combination of individual scientific ... brought together, these offer the opportunity to build ... that will address the urgent need for bringing ... their discovery, antibiotics and other antimicrobial agents have ...
... today that it has been named an American ... Surgery Center of Excellence. The ASMBS Center ... demonstrated track record of favorable outcomes in bariatric ... expertise of our experienced surgeons and our institutional ...
... Denizens of oceans, lakes and even wet soil, diatoms ... glass-like shells. Curiously, these tiny phytoplankton could be harboring ... their hard cell walls by laying down submicron-sized lines ... of the semiconductor industrysilicon. If we can genetically control ...
Cached Biology News:Unique fungal collection could hold key to future antibiotics 2Unique fungal collection could hold key to future antibiotics 3Pennsylvania Hospital recognized for excellence in bariatric surgery 2In diatom, scientists find genes that may level engineering hurdle 2
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
Biology Products: